NCT06151002Recruiting
PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's
PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus. To do this, participants are offered genetic sequencing for two common genetic risk factors for Parkinson's Disease, the GBA1 and LRRK2 gene, with an at-home sample collection kit. Return postage is free.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20000 (estimated)
- First submitted
- 11 Oct 2023
- Start date
- 15 Feb 2020
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- University College, London
- Diseases
- Gaucher disease, Parkinson disease
- NCT number
- NCT06151002
What you commit to
- Study type: Observational
- Planned participants: 20000
- From 15 Feb 2020 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
- Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
Lab values
- Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
Other
- Confirmation that the individual carries a GBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
Who the study is looking for
- Formal diagnosis of Parkinson Disease
Age in the registry: 18 years to 90 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University College London (UCL) Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.